A Phase 2 interventional study of Nemolizumab and Placebo in Dermatitis, Atopic, sponsored by Galderma R&D. Completed at 64 sites in United States. Open to participants aged 12 Years to 54 Years. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing nemolizumab in Dermatitis, Atopic — 3 open to participants now, 3 under way, 1 of them phase 3. nemolizumab · Dermatitis, Atopic.
Among the 14 studies testing nemolizumab in Dermatitis, Atopic, this one is the 5th largest by enrollment, is the only one that started in 2020, is one of 7 in phase 2, and was the 7th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →3 of the 14 studies testing nemolizumab in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:
Galderma R&D · Sites in China
Ages 12+
Galderma R&D · Sites in United States
Ages 6 mo–23 mo
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
nemolizumab: first FDA approval 2024 (NEMLUVIO), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years to 54 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 242 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 209 across the 14 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 14 have an industry lead sponsor. The 3 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
17 studies in Dermatitis, Atopic by Galderma Group AG: 3 open now, 3 under way, 1 of them phase 3. Of 13 finished, 11 (85%) have results posted.
Among the 17 studies in Dermatitis, Atopic by Galderma Group AG, this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2020, is one of 8 in phase 2, and was the 10th registered.
Galderma Group AG’s Dermatitis, Atopic studies by the year they started, since 2009.
1 of the studies testing nemolizumab in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07762833Phase 3Galderma R&DRandomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis | 2027-10-28 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing nemolizumab in Dermatitis, Atopic, from their registry updates:
Among Galderma Group AG’s 17 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effect of nemolizumab (CD14152) on humoral immune responses to tetanus and meningococcal vaccination in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).
This is a randomized, double-blind, placebo-controlled, multi-center, parallel-group study in adult and adolescent participants (≥ 12 to 54 years) with moderate-to-severe AD. Eligible participants must have a documented history of inadequate response to topical AD medication(s). Approximately 200 participants were randomized 1:1 to receive either 30 mg nemolizumab (with a 60 mg loading dose) or placebo, stratified by baseline disease severity Investigator Global Assessment (IGA) (IGA = 3, moderate; IGA = 4, severe). The study consisted of a 2- to 4-week screening period, a 16-week treatment period, and an 8-week follow-up period (12 weeks after the last study drug injection).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a loading dose of nemolizumab (60 milligram \[mg\]) via 2 subcutaneous (SC) injections at baseline. Nemolizumab (30 mg) was administered via a single subcutaneous injection every 4 weeks (Q4W) at Weeks 4, 8, and 12.
Drug: Nemolizumab
Participants received a placebo via 2 SC injections at baseline. Placebo was administered via a single subcutaneous injection Q4W at Weeks 4, 8, and 12.
Drug: Placebo
Nemolizumab was administered by 2 SC injections as 60-mg loading dose at baseline and a single 30-mg dose at Weeks 4, 8, and 12.
Placebo was administered by 2 SC injections at baseline and a single dose at Weeks 4, 8, and 12.
Percentage of Participants With a Positive Serum Immunoglobulin G (IgG) Response (>= 4-Fold Increase or >= 0.2 IU/mL in Anti-Tetanus IgG Concentrations) to Tetanus Toxoid at Week 16 (4 Weeks Post-vaccination)
Percentage of participants with a positive serum IgG response to tetanus toxoid, defined as greater than or equal to (\>=) 4-fold increase in anti-tetanus IgG concentrations from baseline in participants with pre-vaccination anti-tetanus IgG concentrations \>= 0.1 international unit per milliliter (IU/mL); or \>= 0.2 IU/mL anti-tetanus IgG concentrations in participants with pre-vaccination antitetanus IgG concentrations less than (\<) 0.1 IU/mL, at Week 16 (4 weeks post-vaccination) were reported.
Time frame: At Week 16 (4 weeks post-vaccination)
Percentage of Participants With a Positive Serum IgG Response (>=2-Fold Increase or >= 0.2 IU/mL in Anti-tetanus IgG Concentrations) to Tetanus Toxoid at Week 16 (4 Weeks Post-vaccination)
Percentage of participants with a positive serum IgG response to tetanus toxoid, defined as \>= 2-fold increase in anti-tetanus IgG concentrations from baseline in participants with pre-vaccination anti-tetanus IgG concentrations \>= 0.1 IU/mL; or \>= 0.2 IU/mL anti-tetanus IgG concentrations in participants with pre-vaccination Anti tetanus IgG concentrations \< 0.1 IU/mL, at Week 16 (4 weeks post-vaccination) were reported.
Time frame: At Week 16 (4 weeks post-vaccination)
Percentage of Participants With Serum Anti-tetanus IgG Concentrations of >= 0.1 IU/mL at Week 16
Percentage of participants with serum anti-tetanus IgG concentrations of \>= 0.1 IU/mL at Week 16 were reported. The detection and characterization of antibodies to tetanus toxoid was performed using a validated immunoassay.
Time frame: At Week 16
Percentage of Participants With Serum Anti-tetanus IgG Concentrations of >= 1.0 IU/mL at Week 16
Percentage of participants with serum anti-tetanus IgG concentrations of \>= 1.0 IU/mL at Week 16 were reported. The detection and characterization of antibodies to tetanus toxoid was performed using a validated immunoassay.
Time frame: At Week 16
Percentage of Participants With a Positive Serum Bactericidal Antibody (SBA) Response to Meningococcal Serogroup C (MenC) Polysaccharide at Week 16
Percentage of participants with a positive SBA response to meningococcal serogroup C polysaccharide, defined as \>= 4-fold increase in SBA reciprocal titer from baseline (using non-imputed values), at Week 16 (4 weeks postvaccination) were reported.
Time frame: At Week 16
Percentage of Participants With a Positive SBA Response (Defined as SBA Reciprocal Titer ≥8) to MenC Polysaccharide at Week 16
Percentage of participants with a positive SBA response to MenC polysaccharide, defined as SBA reciprocal titer \>= 8, at Week 16 were reported. Immune response to meningococcal vaccination was determined by measuring functional antibody responses using an SBA assay.
Time frame: At Week 16
The study was conducted at 42 sites in United states from 05 Mar 2020 to 07 Jul 2023.
| Milestone | Nemolizumab | Placebo |
|---|---|---|
| Started | 123 | 119 |
| Modified intent to treat (mitt) population | 80 | 78 |
| Safety population | 119 | 115 |
| Completed | 90 | 93 |
| Not completed | 33 | 26 |
| Withdrew: Adverse event | 4 | 2 |
| Withdrew: Participants request | 14 | 14 |
| Withdrew: Lost to follow-up | 8 | 5 |
| Withdrew: Protocol deviation | 3 | 4 |
| Withdrew: Participant compliance with visit schedule | 1 | 0 |
| Withdrew: Participant incarcerated | 1 | 0 |
| Withdrew: Participant moved out of town (relocated) | 0 | 1 |
| Withdrew: Participant pef not eligible per sponsor | 1 | 0 |
| Withdrew: Due to working hours, could not return to other visits | 1 | 0 |
Percentage of participants with a positive serum IgG response to tetanus toxoid, defined as greater than or equal to (\>=) 4-fold increase in anti-tetanus IgG concentrations from baseline in participants with pre-vaccination anti-tetanus IgG concentrations \>= 0.1 international unit per milliliter (IU/mL); or \>= 0.2 IU/mL anti-tetanus IgG concentrations in participants with pre-vaccination antitetanus IgG concentrations less than (\<) 0.1 IU/mL, at Week 16 (4 weeks post-vaccination) were reported.
| Percentage of Participants | Nemolizumab | Placebo |
|---|---|---|
| Percentage of Participants With a Positive Serum Immunoglobulin G (IgG) Response (>= 4-Fold Increase or >= 0.2 IU/mL in Anti-Tetanus IgG Concentrations) to Tetanus Toxoid at Week 16 (4 Weeks Post-vaccination) | 67.5 | 65.4 |
Percentage of participants with a positive serum IgG response to tetanus toxoid, defined as \>= 2-fold increase in anti-tetanus IgG concentrations from baseline in participants with pre-vaccination anti-tetanus IgG concentrations \>= 0.1 IU/mL; or \>= 0.2 IU/mL anti-tetanus IgG concentrations in participants with pre-vaccination Anti tetanus IgG concentrations \< 0.1 IU/mL, at Week 16 (4 weeks post-vaccination) were reported.
| Percentage of Participants | Nemolizumab | Placebo |
|---|---|---|
| Percentage of Participants With a Positive Serum IgG Response (>=2-Fold Increase or >= 0.2 IU/mL in Anti-tetanus IgG Concentrations) to Tetanus Toxoid at Week 16 (4 Weeks Post-vaccination) | 78.8 | 83.3 |
Percentage of participants with serum anti-tetanus IgG concentrations of \>= 0.1 IU/mL at Week 16 were reported. The detection and characterization of antibodies to tetanus toxoid was performed using a validated immunoassay.
| Percentage of Participants | Nemolizumab | Placebo |
|---|---|---|
| Percentage of Participants With Serum Anti-tetanus IgG Concentrations of >= 0.1 IU/mL at Week 16 | 100 | 100 |
Percentage of participants with serum anti-tetanus IgG concentrations of \>= 1.0 IU/mL at Week 16 were reported. The detection and characterization of antibodies to tetanus toxoid was performed using a validated immunoassay.
| Percentage of Participants | Nemolizumab | Placebo |
|---|---|---|
| Percentage of Participants With Serum Anti-tetanus IgG Concentrations of >= 1.0 IU/mL at Week 16 | 97.5 | 96.2 |
Percentage of participants with a positive SBA response to meningococcal serogroup C polysaccharide, defined as \>= 4-fold increase in SBA reciprocal titer from baseline (using non-imputed values), at Week 16 (4 weeks postvaccination) were reported.
| Percentage of Participants | Nemolizumab | Placebo |
|---|---|---|
| Percentage of Participants With a Positive Serum Bactericidal Antibody (SBA) Response to Meningococcal Serogroup C (MenC) Polysaccharide at Week 16 | 77.0 | 63.6 |
Percentage of participants with a positive SBA response to MenC polysaccharide, defined as SBA reciprocal titer \>= 8, at Week 16 were reported. Immune response to meningococcal vaccination was determined by measuring functional antibody responses using an SBA assay.
| Percentage of Participants | Nemolizumab | Placebo |
|---|---|---|
| Percentage of Participants With a Positive SBA Response (Defined as SBA Reciprocal Titer ≥8) to MenC Polysaccharide at Week 16 | 83.3 | 81.9 |
Collected over From Day 1 up to end of study (Week 24). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nemolizumab | 0/119 (0%) | 0/119 (0%) | 44/119 (37%) |
| Placebo | 0/115 (0%) | 1/115 (0.9%) | 38/115 (33%) |
| Event | Nemolizumab | Placebo |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/119 | 1/115 |
| Event | Nemolizumab | Placebo |
|---|---|---|
| Dermatitis atopicSkin and subcutaneous tissue disorders | 13/119 | 6/115 |
| HeadacheNervous system disorders | 6/119 | 1/115 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/119 | 4/115 |
| COVID-19Infections and infestations | 4/119 | 2/115 |
| HyperlipidaemiaMetabolism and nutrition disorders | 3/119 | 1/115 |
| ProteinuriaRenal and urinary disorders | 3/119 | 0/115 |
| Gamma-glutamyltransferase increasedInvestigations | 0/119 | 2/115 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/119 | 2/115 |
| DiarrhoeaGastrointestinal disorders | 1/119 | 2/115 |
| Alanine aminotransferase increasedInvestigations | 2/119 | 1/115 |
Intent-to-Treat Population (ITT) population consisted of all randomized participants.
| Age, Continuous(Years) | Nemolizumab | Placebo | Total |
|---|---|---|---|
| Mean | 35.2 ± 11.62 | 32.1 ± 12.00 | 33.6 ± 11.89 |
| Sex: Female, Male(Participants) | Nemolizumab | Placebo | Total |
|---|---|---|---|
| Female | 78 | 69 | 147 |
| Male | 45 | 50 | 95 |
| Ethnicity (NIH/OMB)(Participants) | Nemolizumab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 43 | 45 | 88 |
| Not Hispanic or Latino | 79 | 73 | 152 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Nemolizumab | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 13 | 19 | 32 |
| Native Hawaiian or Other Pacific Islander | 1 | 2 | 3 |
| Black or African American | 35 | 31 | 66 |
| White | 70 | 62 | 132 |
| More than one race | 1 | 2 | 3 |
| Unknown or Not Reported | 3 | 1 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2020 to primary completion in Jul 2023, 40 months.
Results were first posted in Jun 2025, 1 year 10 months after primary completion. A results delay was requested in Apr 2024.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 40 months is above that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nemolizumab